Floatz logo

Pralsetinib, trans-

Thyroid Diseases

Hoffmann-La RocheSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Thyroid Diseases cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Pralsetinib, trans- is also rated in:

neoplasmDormant
BB
Indicative ·
67 / 100
View asset →
germ cell tumorDormant
BB
Indicative ·
66 / 100
View asset →
respiratory system disorderDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →